Novavax 'confident' in scaling up to 100M vaccine doses by end of year: R&D chief
Novavax has started Phase 1 trials of its vaccine candidate
Get all the latest news on coronavirus and more delivered daily to your inbox. Sign up here.
U.S. biotech company Novavax is "confident" in its ability to scale up to 100 million doses of a coronavirus vaccine by the end of the year after starting Phase 1 trials on a vaccine candidate on Monday, Novavax president of research and development Gregory Glenn said on Tuesday.
"I'm very optimistic with our data that we can come out with a vaccine that's deployable, that could work," Glenn told FOX Business' Stuart Varney. "We think we could make 100 million doses by the end of the year for use."
NOVAVAX STARTS PHASE 1 CORONAVIRUS VACCINE TRIAL AFTER $388M FROM BILL GATES-BACKED GROUP
"We normally wait. ... Confirm it's working, and then you scale it up. We're not waiting. We've begun to scale up to make a vaccine that can be deployed," Glenn said.
Novavax scientist conducing vaccine development research under a laboratory hood. Courtesy Novavax
If its vaccine candidate works, Novavax could scale up to 1.5 billion doses "at least" in 2021, in part thanks to $388 million from the Coalition for Epidemic Preparedness and Innovation, Glenn said.
THIS TYPE OF CRIME IS SPIKING AMID CORONAVIRUS PANDEMIC
Maryland-based Novavax just began dosing for the Phase 1 clinical trial in Australia. If Phase 1 is successful, Novavax will follow up with Phase 2 in multiple countries including the U.S. using participants in a broader age range.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| NVAX | NOVAVAX INC. | 7.67 | -0.10 | -1.29% |
"Vaccines are really miracles. They change lives," Glenn said. "People could walk out the door knowing they're protected. That would be a complete change in the environment we're in."
CLICK HERE TO READ MORE ON FOX BUSINESS
Another U.S. biotech company, Massachusetts-based Moderna, has already started a Phase 1 trial for its vaccine candidate and is reporting optimistic results, making shares jump last week.